Tech Company Financing Transactions

Artiva Biotherapeutics Funding Round

Artiva Biotherapeutics, based in San Diego, received $78 million from 5AM Ventures, venBio and Green Cross Holdings.

Transaction Overview

Company Name
Artiva Biotherapeutics
Announced On
6/26/2020
Transaction Type
Venture Equity
Amount
$78,000,000
Round
Series A
Investors

5AM Ventures (Lead Investor) (Brian Daniels)

venBio (Lead Investor) (Yvonne Yamanaka)

Green Cross Holdings

Medivate Partners

RA Capital (Laura Stoppel)

Proceeds Purpose
Artiva will use the proceeds of this financing to develop off-the-shelf universal NK cells for use in combination with monoclonal antibody therapy and tumor targeting CAR-NK cell therapies.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4747 Executive Dr. 1150
San Diego, CA 92121
USA
Phone
(858) 267-4467
Website
www.artivabio.com
Email Address
[email protected]
Overview
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva's platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.
Profile
Artiva Biotherapeutics LinkedIn Company Profile
Social Media
Artiva Biotherapeutics Company Twitter Account
Company News
Artiva Biotherapeutics News
Facebook
Artiva Biotherapeutics on Facebook
YouTube
Artiva Biotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Fred Aslan
  Fred Aslan LinkedIn Profile  Fred Aslan Twitter Account  Fred Aslan News  Fred Aslan on Facebook
Chief Financial Officer
Esther van den Boom
  Esther van den Boom LinkedIn Profile  Esther van den Boom Twitter Account  Esther van den Boom News  Esther van den Boom on Facebook
Chief Medical Officer
Jason Litten
  Jason Litten LinkedIn Profile  Jason Litten Twitter Account  Jason Litten News  Jason Litten on Facebook
Chief Operating Officer
Peter Flynn
  Peter Flynn LinkedIn Profile  Peter Flynn Twitter Account  Peter Flynn News  Peter Flynn on Facebook
Vice President
Heather Raymon
  Heather Raymon LinkedIn Profile  Heather Raymon Twitter Account  Heather Raymon News  Heather Raymon on Facebook
Vice President
Sungyong Won
  Sungyong Won LinkedIn Profile  Sungyong Won Twitter Account  Sungyong Won News  Sungyong Won on Facebook
VP - Bus. Development
Thomas Farrell
  Thomas Farrell LinkedIn Profile  Thomas Farrell Twitter Account  Thomas Farrell News  Thomas Farrell on Facebook
VP - General Counsel
Jennifer Bush
  Jennifer Bush LinkedIn Profile  Jennifer Bush Twitter Account  Jennifer Bush News  Jennifer Bush on Facebook
VP - Human Resources
Anne Frese
  Anne Frese LinkedIn Profile  Anne Frese Twitter Account  Anne Frese News  Anne Frese on Facebook
VP - Operations
John Lim
  John Lim LinkedIn Profile  John Lim Twitter Account  John Lim News  John Lim on Facebook
VP - Regulatory Affairs
Eugene Helsel
  Eugene Helsel LinkedIn Profile  Eugene Helsel Twitter Account  Eugene Helsel News  Eugene Helsel on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/26/2020: Cryosa venture capital transaction
Next: 6/26/2020: Element Analytics venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.